Efficacy and Safety of Endoscopic Sleeve Gastroplasty at Mid Term in the Management of Overweight and Obese Patients: a Systematic Review and Meta-Analysis

Obes Surg. 2020 May;30(5):1971-1987. doi: 10.1007/s11695-020-04449-9.

Abstract

Background: Endoscopic sleeve gastroplasty (ESG) has emerged as a promising technique in endoscopic bariatric and metabolic therapies (EBMTs). We aimed to perform a systematic review and meta-analysis to provide an update on its efficacy and safety.

Methods: This is a systematic review and meta-analysis was performed following the PRISMA guidelines. MEDLINE, Cochrane, EMBASE, and LILACS were searched to identify the studies related to ESG.

Results: Eleven studies with a total of 2170 patients were included. The average BMI pre-ESG was 35.78 kg/m2. Pooled mean %TWL observed at 6, 12, and 18 months was 15.3%, 16.1%, and 16.8% respectively. Pooled mean %EWL at 6, 12, and 18 months was 55.8%, 60%, and 73% respectively. No procedure-related mortality was reported.

Conclusion: ESG is a safe and effective procedure for primary obesity therapy with promising short- and mid-term results.

Keywords: Bariatric; ESG; Endoscopy; Gastroplasty; Obesity; Overweight; Sleeve; Surgery.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Gastroplasty*
  • Humans
  • Obesity / surgery
  • Obesity, Morbid* / surgery
  • Treatment Outcome
  • Weight Loss